Skip to main content
. 2016 Sep 20;8(1):1774–1787. doi: 10.18632/oncotarget.12152

Figure 2. Prognostic value of the FIB-4 and Metavir scores in the testing set.

Figure 2

Patients were divided into two subgroups according to the FIB-4 and Metavir scores: low (Metavir F1-3 or FIB-4 I ≤ 3.25) and high (Metavir F4 or FIB-4 II > 3.25) scores. A and B: Kaplan-Meier plots of overall survival (OS, A) and recurrence-free survival (RFS, B) with low (FIB-4 I) and high FIB-4 (FIB-4 II) scores in the testing set. C and D: Kaplan-Meier plots of OS C. and RFS D. with low Metavir (F1-3) and high Metavir (F4) scores in the testing set. E and F: Kaplan-Meier estimates of OS E. and RFS F. stratified by the combined Metavir and FIB-4 scores (I: both low; II: low Metavir but high FIB-4; III: high Metavir but low FIB-4; and IV: high Metavir and FIB-4).